ArticlePsoriasis (Auckland, N.Z.)2026

Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study.

Ulrich Mrowietz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.